Repligen Corporation (NASDAQ:RGEN) has received an average recommendation of “Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $37.25.

Several research firms recently issued reports on RGEN. Zacks Investment Research raised shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Wednesday. BidaskClub cut shares of Repligen Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, First Analysis reaffirmed an “equal weight” rating and issued a $40.00 price target on shares of Repligen Corporation in a report on Friday, April 21st.

TRADEMARK VIOLATION NOTICE: “Brokerages Set Repligen Corporation (RGEN) PT at $37.25” was reported by Financial Market News and is the sole property of of Financial Market News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.financial-market-news.com/2017/06/17/brokerages-set-repligen-corporation-rgen-pt-at-37-25.html.

Shares of Repligen Corporation (NASDAQ:RGEN) traded down 0.78% during midday trading on Wednesday, hitting $38.23. 229,107 shares of the stock were exchanged. Repligen Corporation has a 12-month low of $21.45 and a 12-month high of $40.48. The firm has a 50 day moving average of $38.53 and a 200 day moving average of $33.91. The firm has a market cap of $1.30 billion, a P/E ratio of 100.87 and a beta of 1.30.

Repligen Corporation (NASDAQ:RGEN) last posted its earnings results on Thursday, May 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The business had revenue of $30.59 million for the quarter, compared to analysts’ expectations of $29.28 million. Repligen Corporation had a net margin of 11.93% and a return on equity of 9.57%. The business’s revenue for the quarter was up 21.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.12 earnings per share. Equities analysts forecast that Repligen Corporation will post $0.56 EPS for the current fiscal year.

In other Repligen Corporation news, VP Howard Benjamin sold 12,216 shares of the stock in a transaction on Monday, March 20th. The shares were sold at an average price of $34.62, for a total transaction of $422,917.92. Following the sale, the vice president now directly owns 36,124 shares of the company’s stock, valued at $1,250,612.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Thomas F. Ryan, Jr. sold 4,000 shares of the stock in a transaction on Monday, March 20th. The stock was sold at an average price of $34.83, for a total transaction of $139,320.00. Following the sale, the director now directly owns 12,594 shares in the company, valued at $438,649.02. The disclosure for this sale can be found here. Insiders sold 18,737 shares of company stock worth $648,254 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Repligen Corporation during the first quarter worth $103,000. Victory Capital Management Inc. boosted its stake in shares of Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock worth $120,000 after buying an additional 1,475 shares during the period. State of Alaska Department of Revenue boosted its stake in shares of Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock worth $131,000 after buying an additional 80 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock worth $133,000 after buying an additional 908 shares during the period. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Repligen Corporation by 3.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 6,388 shares of the biotechnology company’s stock worth $197,000 after buying an additional 223 shares during the period. 97.06% of the stock is currently owned by institutional investors.

Repligen Corporation Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.